Summary
Development and validation of genetically engineered mouse models (GEMMs) to investigate the liposarcoma tumor microenvironment and facilitate the discovery of new immunotherapeutic approaches.
Genetically engineered mouse models to investigate the liposarcoma microenvironment
US · IL
NIH
grant
open
#nih-5R03CA280126-02
What they want
The project involves two main aims: first, to validate an AAV8-Ap2.2-eGFP/Cre PTEN f/f p53 f/f C57BL/6 LPS GEMM model and characterize its intratumoral and systemic immune responses, comparing the findings to human data to establish its validity as a preclinical model. Second, to generate a Cre-inducible MDM2-overexpressing GEMM to model the most common oncogenic drivers found in human liposarcoma. The successful completion aims to provide necessary models for preclinical studies in sarcoma immunotherapeutics.
Deliverables
- Validated AAV8-Ap2.2-eGFP/Cre PTEN f/f p53 f/f C57BL/6 LPS GEMM model
- Characterization data of intratumoral and systemic immune responses from the validated model
- Cre-inducible MDM2-overexpressing GEMM
Technical requirements
- Expertise in genetically engineered mouse models (GEMMs)
- Capability to validate specific AAV8-Ap2.2-eGFP/Cre PTEN f/f p53 f/f C57BL/6 LPS GEMM model
- Ability to characterize intratumoral and systemic immune responses
- Expertise in generating Cre-inducible MDM2-overexpressing GEMMs
- Understanding of liposarcoma (LPS) biology, MDM2, p53, memory T cells (TRM), and tertiary lymphoid structures (TLS)
